{"url":"https://lda.gov/api/v1/filings/7c73f894-c370-4d9d-b7c0-049865350b0c/","filing_uuid":"7c73f894-c370-4d9d-b7c0-049865350b0c","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2025,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/7c73f894-c370-4d9d-b7c0-049865350b0c/print/","filing_document_content_type":"text/html","income":null,"expenses":"110000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Beth Anne Cole","dt_posted":"2025-04-16T11:38:22-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1550 Liberty Ridge Drive","registrant_address_2":"Suite 115","registrant_different_address":true,"registrant_city":"Wayne","registrant_state":"PA","registrant_zip":"19087","registrant":{"id":401106408,"url":"https://lda.gov/api/v1/registrants/401106408/","house_registrant_id":null,"name":"NOVOCURE INC.","description":"Global oncology company w/a proprietary platform technology called Tumor Treating Fields.","address_1":"1550 Liberty Ridge Drive","address_2":"Suite 115","address_3":null,"address_4":null,"city":"Wayne","state":"PA","state_display":"Pennsylvania","zip":"19087","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"BETH ANNE COLE","contact_telephone":"+1 202-327-8100","dt_updated":"2026-07-16T09:10:06.255740-04:00"},"client":{"id":213758,"url":"https://lda.gov/api/v1/clients/213758/","client_id":12,"name":"NOVOCURE INC.","general_description":null,"client_government_entity":null,"client_self_select":true,"state":"PA","state_display":"Pennsylvania","country":"US","country_display":"United States of America","ppb_state":"PA","ppb_state_display":"Pennsylvania","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2022-01-01"},"lobbying_activities":[{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"General Medicare Issues. H.R.1691/S.5349 - Ensuring Patient Access to Critical Breakthrough Products Act of 2024.","foreign_entity_issues":"Novocure GmbH, Novocure Luxembourg S.a.r.l. (who owns 100% of Novocure GmbH) and NovoCure Limited (who owns 100% of Luxembourg S.a.r.l.), identified on filer's Registration Statement (LD-1), as its parent organization, has an interest in the listed issues.","lobbyists":[{"lobbyist":{"id":139210,"prefix":"ms","prefix_display":"MS.","first_name":"KATHERINE","nickname":"KATIE","middle_name":null,"last_name":"MEYER","suffix":null,"suffix_display":null},"covered_position":"Senior Policy Advisor, Office of House Republican Leader Kevin McCarthy; Deputy Health Policy Director, Senate Finance Committee; Health Policy Advisor, Senator Orrin Hatch; Sr. LA, Congressman Erik Paulsen; LA, Congressman Jeff Fortenberry","new":false},{"lobbyist":{"id":143580,"prefix":null,"prefix_display":null,"first_name":"ZARIA","nickname":null,"middle_name":null,"last_name":"SMITH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147547,"prefix":null,"prefix_display":null,"first_name":"ELLE","nickname":null,"middle_name":null,"last_name":"WHITSON","suffix":null,"suffix_display":null},"covered_position":"Covered Official Positions Continued: Health Policy Advisor, Congresswoman Cathy McMorris Rogers; Staff Assistant / Legislative Correspondent / Legislative Assistant, Congressman Ryan Costello","new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"VET","general_issue_code_display":"Veterans","description":"Veterans Affairs / Veterans Health Administration (VHA) issues.","foreign_entity_issues":"Novocure GmbH, Novocure Luxembourg S.a.r.l. (who owns 100% of Novocure GmbH) and NovoCure Limited (who owns 100% of Luxembourg S.a.r.l.), identified on filer's Registration Statement (LD-1), as its parent organization, has an interest in the listed issues.","lobbyists":[{"lobbyist":{"id":139210,"prefix":"ms","prefix_display":"MS.","first_name":"KATHERINE","nickname":"KATIE","middle_name":null,"last_name":"MEYER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143580,"prefix":null,"prefix_display":null,"first_name":"ZARIA","nickname":null,"middle_name":null,"last_name":"SMITH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147547,"prefix":null,"prefix_display":null,"first_name":"ELLE","nickname":null,"middle_name":null,"last_name":"WHITSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}